Secretory leukoprotease inhibitor: a native antimicrobial protein presenting a new therapeutic option?

JFC Tomee, GH Koeter, PS Hiemstra, HF Kauffman*

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    81 Citations (Scopus)

    Abstract

    Secretory leukoprotease inhibitor (SLPI) is a low molecular weight serine protease inhibitor found on various mucosal surfaces and has been ascribed an important role in maintaining the protease-antiprotease balance of the airways. Recent scientific evidence has suggested that SLPI may also have a broad spectrum antibiotic activity that includes antiretroviral, bactericidal, and antifungal activity. Given the unpropitious development of drug resistance to infectious micro-organisms in the human population, the need for therapeutic alternatives in the treatment of infectious diseases has become clear. SLPI may prove valuable in the prophylaxis and future treatment of infectious diseases, yet the clinical efficacy of SLPI remains largely to be elucidated.

    Original languageEnglish
    Pages (from-to)114-116
    Number of pages3
    JournalThorax
    Volume53
    Issue number2
    Publication statusPublished - Feb-1998

    Keywords

    • secretory leukoprotease
    • inhibitor
    • antimicrobial activity
    • CYSTIC-FIBROSIS
    • ANTILEUKOPROTEASE
    • INFLAMMATION

    Fingerprint

    Dive into the research topics of 'Secretory leukoprotease inhibitor: a native antimicrobial protein presenting a new therapeutic option?'. Together they form a unique fingerprint.

    Cite this